AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 20010420 — intervention group
Group type: EXPERIMENTAL
Intervention: Simulation-based training in hypotensive events (Group 2)
Number of subjects: 21
Study 20010420 — intervention group
Group type: EXPERIMENTAL
Intervention: Final testing at Week 6
Number of subjects: 21
Study 17867950 — intervention group
Group type: EXPERIMENTAL
Intervention: 95% ethanol
Number of subjects: 65
Study 17867950 — intervention group
Group type: COMPARATOR
Intervention: 3% STDS
Number of subjects: 65
Study 16120856 — intervention group
Group type: EXPERIMENTAL
Intervention: Misoprostol (800 microg vaginally)
Number of subjects: 652
Study 16120856 — intervention group
Group type: COMPARATOR
Intervention: Vacuum aspiration (standard of care)
Number of subjects: 652
Study 12133083 — intervention group
Group type: EXPERIMENTAL
Intervention: Nitrous oxide > 40% end tidal concentration
Number of subjects: 21
Study 12133083 — intervention group
Group type: COMPARATOR
Intervention: Nitrous oxide < 10% end tidal concentration
Number of subjects: 21
Study 10093144 — intervention group
Group type: EXPERIMENTAL
Intervention: Dexamethasone
Number of subjects: 0
Study 7487212 — intervention group
Group type: EXPERIMENTAL
Intervention: 80 micrograms/kg body weight recombinant human insulin-like growth factor-I (rhlGF-I)
Number of subjects: 38
Study 7487212 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 38
Study 2225606 — intervention group
Group type: EXPERIMENTAL
Intervention: Prostaglandin treatment (self-administered or given at the clinic)
Number of subjects: 0
Study 2225606 — intervention group
Group type: COMPARATOR
Intervention: Vacuum aspiration
Number of subjects: 0
Study 2225606 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-administered prostaglandin treatment
Number of subjects: 0
Study 2225606 — intervention group
Group type: EXPERIMENTAL
Intervention: Medical procedures (general)
Number of subjects: 0
Study 2225606 — intervention group
Group type: EXPERIMENTAL
Intervention: Surgical procedures (general)
Number of subjects: 0
Study 31030606 — intervention group
Group type: EXPERIMENTAL
Intervention: Perindopril-indapamide treatment
Number of subjects: 10948
Study 31030606 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10948
Study 29725878 — intervention group
Group type: EXPERIMENTAL
Intervention: Peer health navigator intervention with electronic personal health record
Number of subjects: 20
Study 29725878 — intervention group
Group type: COMPARATOR
Intervention: Usual care setting (control group)
Number of subjects: 20
Study 27518661 — intervention group
Group type: EXPERIMENTAL
Intervention: Adalimumab 40 mg weekly
Number of subjects: 633
Study 27518661 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 633
Study 27518661 — intervention group
Group type: EXPERIMENTAL
Intervention: Adalimumab
Number of subjects: 633
Study 27518661 — intervention group
Group type: EXPERIMENTAL
Intervention: Adalimumab and Placebo
Number of subjects: 633
Study 25104617 — intervention group
Group type: EXPERIMENTAL
Intervention: Pemetrexed maintenance (500 mg/m², day 1) plus best supportive care (BSC)
Number of subjects: 539
Study 25104617 — intervention group
Group type: COMPARATOR
Intervention: Placebo plus best supportive care (BSC)
Number of subjects: 539
Study 25104617 — intervention group
Group type: EXPERIMENTAL
Intervention: Pemetrexed maintenance
Number of subjects: 539
Study 25104617 — intervention group
Group type: COMPARATOR
Intervention: Pemetrexed maintenance and Placebo
Number of subjects: 539
Study 22920808 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-partner discrepancy condition
Number of subjects: 135
Study 22920808 — intervention group
Group type: EXPERIMENTAL
Intervention: Moderate-partner discrepancy condition
Number of subjects: 135
Study 22920808 — intervention group
Group type: EXPERIMENTAL
Intervention: High-partner discrepancy condition
Number of subjects: 135
Study 22920808 — intervention group
Group type: COMPARATOR
Intervention: Individual control condition
Number of subjects: 135
Study 20637958 — intervention group
Group type: EXPERIMENTAL
Intervention: FDC ibuprofen 400 mg/paracetamol 1000 mg
Number of subjects: 735
Study 20637958 — intervention group
Group type: EXPERIMENTAL
Intervention: FDC ibuprofen 200 mg/paracetamol 500 mg
Number of subjects: 735
Study 20637958 — intervention group
Group type: EXPERIMENTAL
Intervention: All FDC treatments
Number of subjects: 735
Study 20637958 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 735
Study 20637958 — intervention group
Group type: EXPERIMENTAL
Intervention: Ibuprofen 200 mg
Number of subjects: 735
Study 20637958 — intervention group
Group type: EXPERIMENTAL
Intervention: Ibuprofen 400 mg
Number of subjects: 735
Study 20637958 — intervention group
Group type: EXPERIMENTAL
Intervention: Paracetamol 500 mg
Number of subjects: 735
Study 20637958 — intervention group
Group type: EXPERIMENTAL
Intervention: Paracetamol 1000 mg
Number of subjects: 735
Study 20637958 — intervention group
Group type: EXPERIMENTAL
Intervention: Ibuprofen 100 mg/paracetamol 250 mg
Number of subjects: 735
Study 20637958 — intervention group
Group type: EXPERIMENTAL
Intervention: Ibuprofen 200 mg/paracetamol 500 mg
Number of subjects: 735
Study 20637958 — intervention group
Group type: EXPERIMENTAL
Intervention: Ibuprofen 400 mg/paracetamol 1000 mg
Number of subjects: 735
Study 19463349 — intervention group
Group type: EXPERIMENTAL
Intervention: Percutaneous Coronary Intervention (PCI)
Number of subjects: 1210
Study 19463349 — intervention group
Group type: COMPARATOR
Intervention: Coronary Artery Bypass Grafting (CABG)
Number of subjects: 1210
Study 15770240 — intervention group
Group type: EXPERIMENTAL
Intervention: Citalopram
Number of subjects: 6
Study 15770240 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 6
Study 12858958 — intervention group
Group type: EXPERIMENTAL
Intervention: Grasping (one- and two-handed)
Number of subjects: 0
Study 12858958 — intervention group
Group type: EXPERIMENTAL
Intervention: Comparative judgment
Number of subjects: 0
Study 12858958 — intervention group
Group type: EXPERIMENTAL
Intervention: Manual estimation
Number of subjects: 0
Study 12858958 — intervention group
Group type: EXPERIMENTAL
Intervention: Metric judgment
Number of subjects: 0
Study 12858958 — intervention group
Group type: EXPERIMENTAL
Intervention: Grasping (with elevated disks)
Number of subjects: 0
Study 12858958 — intervention group
Group type: EXPERIMENTAL
Intervention: Manual estimation (with hands visible)
Number of subjects: 0
Study 10963021 — intervention group
Group type: EXPERIMENTAL
Intervention: Speech and language therapy (SLT) involvement
Number of subjects: 16
Study 8886552 — intervention group
Group type: EXPERIMENTAL
Intervention: Radio-opaque markers (ROMs) with a test meal (451 kcal) containing a capsule with 10 ROMs, assessed after 6 hours
Number of subjects: 15
Study 8886552 — intervention group
Group type: EXPERIMENTAL
Intervention: MRI study with 500 ml intralipid 10% (550 kcal)
Number of subjects: 15
Study 8886552 — intervention group
Group type: COMPARATOR
Intervention: MRI study
Number of subjects: 15
Study 1642532 — intervention group
Group type: EXPERIMENTAL
Intervention: Shock group (n=38)
Number of subjects: 132
Study 1642532 — intervention group
Group type: COMPARATOR
Intervention: No shock group (n=94)
Number of subjects: 132
Study 6424492 — intervention group
Group type: EXPERIMENTAL
Intervention: Disodium cromoglycate (DSCG) 20 mg, thrice daily for 3 weeks
Number of subjects: 32
Study 6424492 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 32
Study 31987407 — intervention group
Group type: EXPERIMENTAL
Intervention: Palbociclib at 125 mg daily, 3 weeks on/1 week off for 2 years with endocrine therapy
Number of subjects: 162
Study 31987407 — intervention group
Group type: EXPERIMENTAL
Intervention: Palbociclib
Number of subjects: 162
Study 30014747 — intervention group
Group type: EXPERIMENTAL
Intervention: Subjects with OA risk factors
Number of subjects: 340
Study 30014747 — intervention group
Group type: COMPARATOR
Intervention: Subjects without OA risk factors
Number of subjects: 340
Study 30014747 — intervention group
Group type: COMPARATOR
Intervention: Comparison of prevalence
Number of subjects: 340
Study 26471830 — intervention group
Group type: EXPERIMENTAL
Intervention: Golimumab 50 mg
Number of subjects: 0
Study 26471830 — intervention group
Group type: EXPERIMENTAL
Intervention: Golimumab 100 mg
Number of subjects: 0
Study 26471830 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 26471830 — intervention group
Group type: EXPERIMENTAL
Intervention: Golimumab (both doses)
Number of subjects: 0
Study 23078587 — intervention group
Group type: EXPERIMENTAL
Intervention: Class 1 compression stockings (n = 50)
Number of subjects: 100
Study 23078587 — intervention group
Group type: EXPERIMENTAL
Intervention: Class 2 compression stockings (n = 50)
Number of subjects: 100
Study 23078587 — intervention group
Group type: COMPARATOR
Intervention: Non-compliant patients
Number of subjects: 100
Study 23078587 — intervention group
Group type: COMPARATOR
Intervention: Patients with a history of multiple episodes of ulceration
Number of subjects: 100
Study 23078587 — intervention group
Group type: COMPARATOR
Intervention: Compliant patients
Number of subjects: 100
Study 21862455 — intervention group
Group type: COMPARATOR
Intervention: Placebo + Regular Sodium Diet (RS)
Number of subjects: 33
Study 21862455 — intervention group
Group type: EXPERIMENTAL
Intervention: Low Sodium Diet (LS)
Number of subjects: 33
Study 21862455 — intervention group
Group type: EXPERIMENTAL
Intervention: Angiotensin Receptor Blockade (ARB; losartan 100 mg/day)
Number of subjects: 33
Study 21862455 — intervention group
Group type: EXPERIMENTAL
Intervention: ARB + Diuretics (losartan 100 mg/day plus hydrochlorothiazide 25 mg/day)
Number of subjects: 33
Study 21862455 — intervention group
Group type: EXPERIMENTAL
Intervention: LS and Diuretics
Number of subjects: 33
Study 19291085 — intervention group
Group type: EXPERIMENTAL
Intervention: Daunorubicin 50 mg/m(2)
Number of subjects: 1273
Study 19291085 — intervention group
Group type: COMPARATOR
Intervention: Daunorubicin 35 mg/m(2)
Number of subjects: 1273
Study 19291085 — intervention group
Group type: EXPERIMENTAL
Intervention: Cytarabine 200 mg/m(2)
Number of subjects: 1273
Study 19291085 — intervention group
Group type: COMPARATOR
Intervention: Cytarabine 400 mg/m(2)
Number of subjects: 1273
Study 19291085 — intervention group
Group type: EXPERIMENTAL
Intervention: PSC‐833 (multidrug resistance modulator)
Number of subjects: 1273
Study 19291085 — intervention group
Group type: COMPARATOR
Intervention: Three courses of treatment
Number of subjects: 1273
Study 19291085 — intervention group
Group type: EXPERIMENTAL
Intervention: Four courses of treatment
Number of subjects: 1273
Study 17975181 — intervention group
Group type: EXPERIMENTAL
Intervention: Risperidone 1 mg/d (increased to 2 mg/d after 4 weeks if needed)
Number of subjects: 274
Study 17975181 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 274
Study 17975181 — intervention group
Group type: EXPERIMENTAL
Intervention: Risperidone
Number of subjects: 274
Study 15304577 — intervention group
Group type: EXPERIMENTAL
Intervention: Anticoagulant treatment
Number of subjects: 1281
Study 15304577 — intervention group
Group type: EXPERIMENTAL
Intervention: Cortical lesions
Number of subjects: 1281
Study 15304577 — intervention group
Group type: EXPERIMENTAL
Intervention: Increasing age
Number of subjects: 1281
Study 15304577 — intervention group
Group type: EXPERIMENTAL
Intervention: Gender and handedness
Number of subjects: 1281
Study 11843951 — intervention group
Group type: EXPERIMENTAL
Intervention: Ramipril
Number of subjects: 9297
Study 11843951 — intervention group
Group type: EXPERIMENTAL
Intervention: Ramipril 10 mg
Number of subjects: 9297
Study 9689829 — intervention group
Group type: EXPERIMENTAL
Intervention: T4 replacement therapy in Group A (Congenital Hypothyroidism)
Number of subjects: 12
Study 9689829 — intervention group
Group type: COMPARATOR
Intervention: Control group B (matched for age, sex, weight, and pubertal stage)
Number of subjects: 12
Study 9689829 — intervention group
Group type: COMPARATOR
Intervention: Control group C (matched for age, sex, weight, and pubertal stage)
Number of subjects: 12
Study 9689829 — intervention group
Group type: EXPERIMENTAL
Intervention: Long-term T4 replacement therapy
Number of subjects: 12
Study 8106768 — intervention group
Group type: EXPERIMENTAL
Intervention: Teicoplanin (6 mg/kg every 24 h i.v. after initial loading every 12 h for three doses)
Number of subjects: 46
Study 8106768 — intervention group
Group type: COMPARATOR
Intervention: Vancomycin (15 mg/kg every 12 h i.v.)
Number of subjects: 46
Study 8106768 — intervention group
Group type: COMPARATOR
Intervention: Vancomycin
Number of subjects: 46
Study 8106768 — intervention group
Group type: EXPERIMENTAL
Intervention: Teicoplanin
Number of subjects: 46
Study 2566337 — intervention group
Group type: EXPERIMENTAL
Intervention: 25 mg almitrine bismesylate
Number of subjects: 10
Study 2566337 — intervention group
Group type: EXPERIMENTAL
Intervention: 50 mg almitrine bismesylate
Number of subjects: 10
Study 2566337 — intervention group
Group type: EXPERIMENTAL
Intervention: 100 mg almitrine bismesylate
Number of subjects: 10
Study 2566337 — intervention group
Group type: EXPERIMENTAL
Intervention: 200 mg almitrine bismesylate
Number of subjects: 10
Study 2566337 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10
Study 4443866 — intervention group
Group type: EXPERIMENTAL
Intervention: Rewarming at 38 degrees C skin surface temperature
Number of subjects: 42
Study 4443866 — intervention group
Group type: COMPARATOR
Intervention: Rewarming at 35 degrees C skin surface temperature
Number of subjects: 42
Study 4443866 — intervention group
Group type: COMPARATOR
Intervention: Rewarming at 36 degrees C skin surface temperature
Number of subjects: 42
Study 4443866 — intervention group
Group type: COMPARATOR
Intervention: Rewarming at 37 degrees C skin surface temperature
Number of subjects: 42
Study 29016549 — intervention group
Group type: EXPERIMENTAL
Intervention: Metformin (MET)
Number of subjects: 3187
Study 29016549 — intervention group
Group type: EXPERIMENTAL
Intervention: Lifestyle intervention (ILS)
Number of subjects: 3187
Study 29016549 — intervention group
Group type: COMPARATOR
Intervention: Placebo (PLB)
Number of subjects: 3187
Study 29016549 — intervention group
Group type: EXPERIMENTAL
Intervention: All groups
Number of subjects: 3187
Study 28802552 — intervention group
Group type: EXPERIMENTAL
Intervention: Pigtail-retained gastrostomy (PG)
Number of subjects: 100
Study 28802552 — intervention group
Group type: COMPARATOR
Intervention: Mushroom-retained gastrostomy (MG)
Number of subjects: 100
Study 26315143 — intervention group
Group type: EXPERIMENTAL
Intervention: Coping-infused dialogue through patient-preferred live music (CID-PPLM)
Number of subjects: 25
Study 26315143 — intervention group
Group type: COMPARATOR
Intervention: Usual care (control)
Number of subjects: 25
Study 23664987 — intervention group
Group type: EXPERIMENTAL
Intervention: IMVAMUNE (0+7 schedule)
Number of subjects: 208
Study 23664987 — intervention group
Group type: EXPERIMENTAL
Intervention: IMVAMUNE (0+28 schedule)
Number of subjects: 208
Study 23664987 — intervention group
Group type: EXPERIMENTAL
Intervention: IMVAMUNE (0 schedule)
Number of subjects: 208
Study 23664987 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 208
Study 22028630 — intervention group
Group type: EXPERIMENTAL
Intervention: PCV-7 vaccination in 11 vaccinated villages
Number of subjects: 5441
Study 22028630 — intervention group
Group type: COMPARATOR
Intervention: Meningococcal serogroup C conjugate vaccine in 10 control villages
Number of subjects: 5441
Study 22028630 — intervention group
Group type: EXPERIMENTAL
Intervention: PCV-7 vaccination
Number of subjects: 5441
Study 18435772 — intervention group
Group type: COMPARATOR
Intervention: Diet only (D)
Number of subjects: 29
Study 18435772 — intervention group
Group type: EXPERIMENTAL
Intervention: Diet plus exercise (DE)
Number of subjects: 29
Study 15922233 — intervention group
Group type: EXPERIMENTAL
Intervention: Thoracic spine manipulation
Number of subjects: 0
Study 15922233 — intervention group
Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 0
Study 12584834 — intervention group
Group type: EXPERIMENTAL
Intervention: Composite Salvia Injection (CSI)
Number of subjects: 68
Study 12584834 — intervention group
Group type: COMPARATOR
Intervention: Xueshuantong (Control)
Number of subjects: 68
Study 10511060 — intervention group
Group type: EXPERIMENTAL
Intervention: Clenoliximab (IDEC‐151), a chimeric monoclonal antibody, administered as a single intravenous infusion.
Number of subjects: 0
Study 8555987 — intervention group
Group type: EXPERIMENTAL
Intervention: Almitrine 50 mg twice a day by mouth for 60 days
Number of subjects: 18
Study 8555987 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 18
Study 8555987 — intervention group
Group type: EXPERIMENTAL
Intervention: Almitrine
Number of subjects: 18
Study 1785379 — intervention group
Group type: EXPERIMENTAL
Intervention: Neoadjuvant cyclophosphamide + doxorubicin + cisplatin (CAP) plus radiation therapy
Number of subjects: 43
Study 1785379 — intervention group
Group type: COMPARATOR
Intervention: Control group (no specific intervention mentioned)
Number of subjects: 43
Study 1785379 — intervention group
Group type: EXPERIMENTAL
Intervention: Neoadjuvant methotrexate + vinblastine + doxorubicin + cisplatin (M‐VAC) therapy
Number of subjects: 43
Study 7059418 — intervention group
Group type: COMPARATOR
Intervention: Hydrochlorothiazide 100 mg daily
Number of subjects: 18
Study 7059418 — intervention group
Group type: EXPERIMENTAL
Intervention: Hydrochlorothiazide plus acebutolol (up to 800 mg daily)
Number of subjects: 18
Study 7059418 — intervention group
Group type: EXPERIMENTAL
Intervention: Acebutolol (up to 2000 mg daily)
Number of subjects: 18
Study 31664428 — intervention group
Group type: EXPERIMENTAL
Intervention: Bariatric surgery (gastric bypass, banding, vertical banded gastroplasty)
Number of subjects: 2007
Study 28534645 — intervention group
Group type: EXPERIMENTAL
Intervention: Elamipretide
Number of subjects: 19
Study 28534645 — intervention group
Group type: COMPARATOR
Intervention: Healthy controls
Number of subjects: 19
Study 29386749 — intervention group
Group type: EXPERIMENTAL
Intervention: Telematic cognitive stimulation (TCS)
Number of subjects: 98
Study 29386749 — intervention group
Group type: EXPERIMENTAL
Intervention: Mixed TCS/FCS
Number of subjects: 98
Study 29386749 — intervention group
Group type: COMPARATOR
Intervention: Control group (no intervention specified)
Number of subjects: 98
Study 26078713 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.3% gatifloxacin ophthalmic gel
Number of subjects: 150
Study 26078713 — intervention group
Group type: COMPARATOR
Intervention: 0.3% gatifloxacin ophthalmic solution
Number of subjects: 150
Study 26078713 — intervention group
Group type: COMPARATOR
Intervention: 0.5% levofloxacin ophthalmic solution
Number of subjects: 150
Study 25057270 — intervention group
Group type: EXPERIMENTAL
Intervention: Ginkgo biloba extract EGb 761 (240 mg per day)
Number of subjects: 160
Study 25057270 — intervention group
Group type: COMPARATOR
Intervention: Betahistine (32 mg per day)
Number of subjects: 160
Study 25057270 — intervention group
Group type: EXPERIMENTAL
Intervention: Ginkgo biloba extract EGb 761
Number of subjects: 160
Study 25057270 — intervention group
Group type: COMPARATOR
Intervention: Betahistine
Number of subjects: 160
Study 21138337 — intervention group
Group type: EXPERIMENTAL
Intervention: Tobramycin/dexamethasone ophthalmic suspension 0.3%/0.05% (TobraDex ST) dosed 1 drop QID for 14 days
Number of subjects: 122
Study 21138337 — intervention group
Group type: COMPARATOR
Intervention: Azithromycin ophthalmic solution 1% dosed 1 drop BID for 2 days followed by QD for 12 days
Number of subjects: 122
Study 22435514 — intervention group
Group type: EXPERIMENTAL
Intervention: Artichoke juice concentrate (50 mg)
Number of subjects: 0
Study 22435514 — intervention group
Group type: EXPERIMENTAL
Intervention: Artichoke juice concentrate (100 mg)
Number of subjects: 0
Study 22435514 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 17570960 — intervention group
Group type: EXPERIMENTAL
Intervention: Group therapy through Internet chat (12-15 weeks, 90 min weekly)
Number of subjects: 114
Study 17570960 — intervention group
Group type: COMPARATOR
Intervention: Control group (no participation in chat groups)
Number of subjects: 114
Study 15210929 — intervention group
Group type: EXPERIMENTAL
Intervention: Direct bracket placement
Number of subjects: 26
Study 15210929 — intervention group
Group type: COMPARATOR
Intervention: Indirect bracket placement
Number of subjects: 26
Study 11816130 — intervention group
Group type: EXPERIMENTAL
Intervention: Kreon 25,000 U lipase (A); 3 x 1 caps/day for 2 weeks
Number of subjects: 60
Study 11816130 — intervention group
Group type: EXPERIMENTAL
Intervention: Kreon 10,000 U lipase (B); 3 x 1 caps/day for 2 weeks
Number of subjects: 60
Study 11816130 — intervention group
Group type: COMPARATOR
Intervention: Placebo; 3 x 1 caps/day for 2 weeks
Number of subjects: 60
Study 9806693 — intervention group
Group type: EXPERIMENTAL
Intervention: Lidocaine 0.5% with fentanyl 0.001% (10 microg) for wound infiltration
Number of subjects: 20
Study 9806693 — intervention group
Group type: COMPARATOR
Intervention: Lidocaine 0.5% alone (fentanyl 10 microg IM contralaterally)
Number of subjects: 20
Study 7711339 — intervention group
Group type: EXPERIMENTAL
Intervention: Ketoconazole 400 mg
Number of subjects: 8
Study 7711339 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluconazole 100 mg
Number of subjects: 8
Study 2599722 — intervention group
Group type: EXPERIMENTAL
Intervention: Heavy training load
Number of subjects: 15
Study 2599722 — intervention group
Group type: COMPARATOR
Intervention: Light training load
Number of subjects: 15
Study 17894051 — intervention group
Group type: EXPERIMENTAL
Intervention: L-Tryptophan treatment
Number of subjects: 9
Study 17894051 — intervention group
Group type: COMPARATOR
Intervention: Control (no treatment with L-Tryptophan)
Number of subjects: 9
Study 31733631 — intervention group
Group type: EXPERIMENTAL
Intervention: LSD (0.1 mg)
Number of subjects: 28
Study 31733631 — intervention group
Group type: EXPERIMENTAL
Intervention: MDMA (125 mg)
Number of subjects: 28
Study 31733631 — intervention group
Group type: EXPERIMENTAL
Intervention: d-amphetamine (40 mg)
Number of subjects: 28
Study 31733631 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 28
Study 31733631 — intervention group
Group type: EXPERIMENTAL
Intervention: All substances
Number of subjects: 28
Study 30653847 — intervention group
Group type: EXPERIMENTAL
Intervention: Liraglutide (0.3 mg starting dose, escalating to 3.0 mg or maximum tolerated dose)
Number of subjects: 24
Study 30653847 — intervention group
Group type: EXPERIMENTAL
Intervention: Liraglutide
Number of subjects: 24
Study 30653847 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 24
Study 28173938 — intervention group
Group type: EXPERIMENTAL
Intervention: Spinal anesthesia
Number of subjects: 70